## MMC: Marsh & McLennan Companies, Inc - XLF: Financial Services

### Executive Summary

No thesis match: MRS_10 0.0% below STRENGTH zone (3.0-6.0%); PEG 2.00 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($177.53)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. The Manufacturers Life Insurance Company Purchases 593,353 Shares of Marsh & McLennan Companies, Inc. $MMC**
- Source: MarketBeat | 20251211T141845 | Somewhat-Bullish | Relevance: 99%
- The Manufacturers Life Insurance Company significantly increased its stake in Marsh & McLennan Companies, Inc. (NYSE:MMC) by 79.3% in Q2, acquiring an additional 593,353 shares, bringing its total holdings to 1,341,359 shares valued at $293.3 million. This increase makes them a substantial institutional investor, holding 0.27% of the company's stock. Other institutional investors also adjusted their positions, while CEO John Q. Doyle sold a portion of his shares.

**2. Ossiam Has $4.02 Million Stock Position in Marsh & McLennan Companies, Inc. $MMC**
- Source: MarketBeat | 20251209T124545 | Neutral | Relevance: 98%
-  Ossiam significantly increased its stake in Marsh & McLennan Companies by 75.8% in Q2, boosting its holdings to 18,378 shares valued at approximately $4.02 million. Meanwhile, CEO John Q. Doyle sold over 21,000 shares for $3.84 million, reducing his insider position. The company reported strong Q3 earnings, beating analyst expectations, and maintains a "Hold" consensus rating with a $223 average target price.

**3. Axa S.A. Sells 7,842 Shares of Marsh & McLennan Companies, Inc. $MMC**
- Source: MarketBeat | 20251210T090845 | Neutral | Relevance: 98%
- Axa S.A. has reduced its stake in Marsh & McLennan Companies, Inc. (NYSE:MMC) by 4.0% in the second quarter, selling 7,842 shares and now owning 189,785 shares valued at $41,495,000. Other institutional investors have also adjusted their positions in MMC, while company CEO John Q. Doyle recently sold 21,079 shares. Analysts have issued varied ratings for MMC, with an average "Hold" rating and a price target of $223.00, following recent earnings that beat consensus estimates.

**4. Natixis Lowers Holdings in Marsh & McLennan Companies, Inc. $MMC**
- Source: MarketBeat | 20251209T123545 | Neutral | Relevance: 98%
-  Natixis significantly reduced its stake in Marsh & McLennan Companies by 37.4% in the second quarter, selling over 36,000 shares. This comes amidst other institutional investor activity and various analyst price target adjustments, though the consensus rating remains "Hold." Meanwhile, CEO John Q. Doyle also sold a portion of his shares, reducing his position by nearly 20%.

**5. Marsh & McLennan Companies, Inc. $MMC Shares Sold by State Street Corp**
- Source: MarketBeat | 20251209T131345 | Neutral | Relevance: 97%
-  State Street Corp reduced its stake in Marsh & McLennan Companies by 0.2% in Q2, selling 48,901 shares, while CEO John Q. Doyle also sold 21,079 shares for $3.84 million in early December. Despite recent target cuts from analysts, the company maintains a consensus "Hold" rating with an average $223 price target, having recently outperformed Q3 EPS estimates and reported an 11.5% year-over-year revenue increase. The company also announced a quarterly dividend of $0.90 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Citigroup | $201 | $211 | -5% |
| 2025-11-20 | Barclays | $206 | $221 | -7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Citigroup | main | Neutral |
| 2025-11-20 | Barclays | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.28M) |
| Sells | 1 ($3.84M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.1%)
- Blackrock Inc.: 7.9% (-3.7%)
- State Street Corpora: 4.4% (+0.4%)
- Capital Internationa: 3.8% (+1.2%)
- Capital World Invest: 3.6% (+0.5%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. Long-term trend broken: trading 12.9% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.00 elevated, pricing in significant growth expectations. Forward P/E 17.8x stretched relative to 7% growth. Quality metrics strong (ROE 29%, margin 16%). Balance sheet: $2.3B free cash flow. Analyst sentiment negative (2 target cuts vs 0 raises). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $90.2B |
| Beta | 0.75 |
| 52W Range | $174.18 - $248.00 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.00 |
| Forward P/E | 17.8 |
| Current P/E | 19.1 |
| YoY Growth | 7.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.0% to 0.0% (+2.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.0pp (needs >3.0% for momentum thesis). Below SMA200 (0.87x), long-term trend not supportive. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.00% (CS: 38) | Neutral |
| RSI_14 | 51.2 | Neutral |
| MACD Histogram | 0.46 | Bullish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 0.982x | Below |
| vs SMA200 | 0.871x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $183.47
- **Stop Loss:** $177.53 (3.2% risk)
- **Target:** $189.41 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 232
- **Position Value:** $42,565.04
- **Portfolio %:** 42.57%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-29 (Est: $1.97)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.85 | +4.1% |
| 2025Q2 | $2.66 | $2.72 | +2.1% |
| 2025Q1 | $3.00 | $3.06 | +2.1% |
| 2024Q4 | $1.76 | $1.87 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*